Searchable abstracts of presentations at key conferences in endocrinology
ISSN 1470-3947 (print)
| ISSN 1479-6848 (online)
Endocrine Abstracts
Menu
Search
Issues/Conferences
Cite
About
Our Services
Policies
Contact
Disclaimer
Search
Issues/Conferences
Cite
About
Our Services
Policies
Contact
Disclaimer
Previous issue
|
Volume 52
|
UKINETS2017
|
Next issue
UKI NETS 15th National Conference
All volumes
0104 SFEIES24
0103 BSPED2024
0102 EYES2024
0101 ETA2024
0100 SFEEU2024
0099 ECE2024
0098 NANETS2023
0097 BES2023
0096 UKINETS2023
0095 BSPED2023
0094 SFEBES2023
0093 EYES2023
0092 ETA2023
0091 SFEEU2023
0090 ECE2023
0089 NANETS2022
0088 BES2022
0087 UKINETS2022
0086 SFEBES2022
0085 BSPED2022
0084 ETA2022
0083 EYES2022
0082 SFEEU2022
0081 ECE2022
0080 UKINETS2021
0079 BES2021
0078 BSPED2021
0077 SFEBES2021
0076 CHD2021
0075 EYES2021
0074 SFENCC2021
0073 ECE2021
0072 UKINETS2020
0071 BES2020
0070 ECE2020
0069 SFENCC2020
0068 UKINETS2019
0067 EYES2019
0066 BSPED2019
0065 SFEBES2019
0064 BES2019
0063 ECE2019
0062 EU2019
0061 OU2019
0060 UKINETS2018
0059 SFEBES2018
0058 BSPED2018
0057 BES2018
0056 ECE2018
0055 SFEEU2018
0054 NuclearReceptors2018
0053 OU2018
0052 UKINETS2017
0051 BSPED2017
0050 SFEBES2017
0049 ECE2017
0048 SFEEU2017
0047 Theranostics2016
0046 UKINETS2016
0045 BSPED2016
0044 SFEBES2016
0043 WCTD2016
0042 Androgens2016
0041 ECE2016
0040 ESEBEC2016
0039 BSPED2015
0038 SFEBES2015
0037 ECE2015
0036 BSPED2014
0035 ECE2014
0034 SFEBES2014
0033 BSPED2013
0032 ECE2013
0031 SFEBES2013
0030 BSPED2012
0029 ICEECE2012
0028 SFEBES2012
0027 BSPED2011
0026 ECE2011
0025 SFEBES2011
0024 BSPED2010
0023 BSPED2009
0022 ECE2010
0021 SFEBES2009
0020 ECE2009
0019 SFEBES2009
0018 MES2008
0017 BSPED2008
0016 ECE2008
0015 SFEBES2008
0014 ECE2007
0013 SFEBES2007
0012 SFE2006
0011 ECE2006
0010 SFE2005
0009 BES2005
0008 SFE2004
0007 BES2004
0006 SFE2003
0005 BES2003
0004 SFE2002
0003 BES2002
0002 SFE2001
Summary
Abstract Book
Volume Editors
Abstracts
Contents
15th Annual Meeting of the UK and Ireland Neuroendocrine Tumour Society 2017
Speaker Abstracts
The role of biomarkers in the management of neuroendocrine tumours
ea0052nets1
The role of pathology and the new WHO classification
ea0052nets2
Abstract unavailable
ea0052nets3
Role of Multimodality Imaging
ea0052nets4
Neo-adjuvant and adjuvant treatment in bronchial NETs
ea0052nets5
Type I gastric NETs: Surveillance, Endoscopic Resection or Surgery
ea0052nets6
Refractory hypoglycaemia in advanced insulinomas
ea0052nets7
Abstract unavailable
ea0052nets8
Abstract unavailable
ea0052nets9
Abstract unavailable
ea0052nets10
Debate: There is a role in resection of NET hepatic metastases - surgical dilemma
ea0052nets11
Abstract unavailable
ea0052nets12
Abstract unavailable
ea0052nets13
Abstract unavailable
ea0052nets14
The evolving landscape in Nuclear Medicine in NETs
ea0052nets15
Abstract unavailable
ea0052nets16
Oral Communications
(1)
A predictive quotient index, comprising neuroendocrine gene cluster analysis in blood and tissue grading is specifically predicts PRRT efficacy
ea0052oc1
Systematic evaluation of the immune microenvironment of neuroendocrine tumours
ea0052oc2
Incidence and prevalence of neuroendocrine tumours in England
ea0052oc3
Poster Presentations
(1)
Genetics and diagnostic characterisation of bladder paragangliomas
ea0052p01
Validation of a blood biomarker test for the diagnosis and management of bronchopulmonary neuroendocrine tumors
ea0052p02
Blood measurements of Neuroendocrine Tumor (NET) transcripts and gene cluster analysis predict efficacy of PRRT
ea0052p03
A liquid biopsy for the diagnosis and monitoring of bronchopulmonary/lung carcinoid
ea0052p04
Incidence of PCC/PGL in mutation positive family members at first contact
ea0052p05
Nutritional assessment and vitamin deficiencies in patients with NETs
ea0052p06
Piloting a group programme aiming at psychologically supporting neuroendocrine patients
ea0052p07
Audit of a new nurse-led non-medical prescribing (NMP) clinic for systemic anti-cancer agents (SACTs)
ea0052p08
Audit of South Wales Neuroendocrine MDT pathology reports
ea0052p09
Neuroendocrine Tumour (NET) patients experiences of support in the community setting across the cancer treatment trajectory
ea0052p10
The Missing Malignancies - Follow up of patients with pulmonary carcinoid tumours in the UK: Results from the National Lung NET Pathway ('LEAP') project
ea0052p11
1-Year survival rates for neuroendocrine tumour patients in England
ea0052p12
Metachronous primary cancers in neuroendocrine tumour patients
ea0052p13
Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period
ea0052p14
Platinum-etoposide chemotherapy for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC): A survey of clinical practice
ea0052p15
Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: post-hoc analyses from TELESTAR
ea0052p16
Surgical therapy for appendiceal neuroendocrine tumours: is appendicectomy adequate?
ea0052p17
Circulating Tumour Cells (CTCs) are associated with bone metastases in patients with Neuroendocrine Tumours (NET)
ea0052p18
Mixed Adeno-Neuroendocrine Carcinoma (MANEC): a multicentre retrospective study
ea0052p19
Prophylactic right hemicolectomy in Appendiceal Neuroendocrine Neoplasms: challenging the current indications
ea0052p20
Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence
ea0052p21
Above-label doses of lanreotide Autogel for the treatment of advanced neuroendocrine tumours (NETs)
ea0052p23
Shortened interval of octreotide LAR administration for the treatment of advanced neuroendocrine tumours (NETs)
ea0052p24
Multi-parametric assessment improves prognostication of small bowel neuroendocrine neoplasms: external validation of the NET nomogram
ea0052p26
Supplementation of vitamin D deficiency/insufficiency in patients with GEP-NET using over the counter vitamin D3 preparations
ea0052p27
Outcomes of radical treatment of NET Liver Metastases: a single tertiary centre 18-year experience
ea0052p28
Endoscopic submucosal dissection (ESD) of gastric and rectal neuroendocrine tumours (NETs)
ea0052p29
Outcomes of surgical and endoscopic resection of duodenal NETs: a systematic review of the literature
ea0052p30
The utility of the KI67-Index in predicting pulmonary carcinoid metastasis: a single centre experience
ea0052p31
Impact of somatostatin analogues on quality of life in patients with neuroendocrine tumours
ea0052p32
Double-balloon enteroscopy (DBE) is useful and effective for the diagnosis, assessment and management of small bowel neuroendocrine tumours (SBNETs): a case series from a national tertiary referral centre
ea0052p33
Grading systems in gastroenteropancreatic neuroendocrine tumours
ea0052p34
A family of SDHB mutation and paraganglioma Alam K, Owen D, Ganatra R, Nakas A, Lloyd D, Levy MJ university hospitals of Leicester NHS trust
ea0052p35
Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours
ea0052p36
Choroidal metastases as a Harbinger of Metastatic Typical Pulmonary Carcinoid: regression and stability with Lanreotide autogel
ea0052p37
Paraneoplastic syndrome or De Novo diagnosis?: Metastatic small bowel neuroendocrine tumour presenting with Giant cell arteritis
ea0052p38
A case of carcinoid crisis despite high dose somatostatin analogue therapy peri-operatively
ea0052p39
Pancreatic VIPoma - a diagnostic and symptom control challenge
ea0052p40
Two cases of metastatic neuroendocrine tumours stabilised with somatostatin analogues
ea0052p41
Therapeutic options in metastatic phaeochromocytomas
ea0052p42